Barhemsys Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
1
Barhemsys General Information
Description
Provider of pharmaceutical treatments for postoperative care based in the healthcare market. The company develops antiemetic medications such as Barhemsys, which target dopamine receptors to address postoperative nausea and vomiting, offering options for patients who do not respond to other therapies.
Contact Information
Website
www.barhemsys.com(Operating Subsidiary)
Corporate Office
- United States
Corporate Office
- United States
Barhemsys Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Barhemsys Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Barhemsys FAQs
-
Where is Barhemsys headquartered?
Barhemsys is headquartered in .
-
What industry is Barhemsys in?
Barhemsys’s primary industry is Drug Discovery.
-
Is Barhemsys a private or public company?
Barhemsys is a Private company.
-
What is Barhemsys’s current revenue?
The current revenue for Barhemsys is .
-
Who are Barhemsys’s investors?
Eagle Pharmaceuticals has invested in Barhemsys.
-
When was Barhemsys acquired?
Barhemsys was acquired on 14-Jan-2026.
-
Who acquired Barhemsys?
Barhemsys was acquired by LXO Group.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process